About Curadel Pharma
Curadel Pharma is a private company based in Bonita Springs, Florida. It has reported $75,854,238 raised in four offerings on Form D since June 2023. Its chief executive is John Frangioni, M.D., Ph.D..
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Oct 13, 2026 | $49,844,295of $57.5M target | 39 | $1.2M | Equity, Convertible Notes converting into equity.Rule 506(b) | Form D ↗ |
| Sep 25, 2025 | Oct 9, 2025 | $14,479,902of $20.0M target | 25 | $579K | EquityRule 506(b) | Form D ↗ |
| Sep 4, 2024 | Sep 18, 2024amended Jan 8, 2025 | $9,530,050of $10.5M target | 27 | $352K | Equity, Convertible Security SharesRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 5, 2023 | Jun 13, 2023 | $1,999,991fully sold | 10 | $199K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $75,854,238 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Curadel Pharma's Form D filed Oct 13, 2026.
JD
John Frangioni, M.D., Ph.D.
Chief Executive Officer and director
GB
Garen Bohlin
Director
MD
Marc Garnick, M.D.
Director
SS
Sean Stalfort
Director
WF
Walid Fakhry
Director
Earlier filings also listed Marc Garnick (director, last listed Oct 2025) and Henry Kay (director, last listed Oct 2025).